COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland
The obtained results indicate a naturally more significant humoral response in oncological patients who have not been vaccinated and have not undergone anticancer therapy, such as radiotherapy, chemotherapy, or surgical intervention. The above observation applies to patients with breast, lung, colon, kidney, and testicular cancer, although the response varies significantly depending on the type of cancer.
Authors
- Piotr Kosiorek (ORCID: https://orcid.org/0000-0001-8428-2225)
- Bożena Mikołuć (ORCID: https://orcid.org/0000-0002-8284-6426)
- Dorota Kazberuk
- Robert Milewski (ORCID: https://orcid.org/0000-0001-6241-8283)
- Anna Stasiak‐Barmuta
- Anna Grzeszczuk (ORCID: https://orcid.org/0000-0002-6420-5545)
- Samuel Stróż (ORCID: https://orcid.org/0000-0001-8732-7935)
- Anna Hryniewicz (ORCID: https://orcid.org/0000-0003-0351-5547)
- Magdalena Borkowska (ORCID: https://orcid.org/0000-0001-7659-4448)
Institutions
- Medical University of Białystok (PL)
- Maria Curie-Skłodowska University (PL)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1007/s00262-024-03895-z
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00